# Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors

> **NCT03628131** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 46 (estimated)

## Conditions studied

- Relapsed Pediatric Solid Tumor
- Refractory Pediatric Solid Tumor

## Interventions

- **DRUG:** Pazopanib
- **DRUG:** Ifosfamide
- **DRUG:** Carboplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT03628131
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10
- **Primary completion:** 2023-07
- **Final completion:** 2025-07
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2018-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03628131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03628131, "Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03628131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*